^
    1d
    Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC (clinicaltrials.gov)
    P2, N=318, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Initiation date: Jan 2025 --> Jun 2025
    Trial initiation date • Real-world evidence
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed
    1d
    TROPION Lung15: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=744, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial completion date: May 2028 --> Sep 2028 | Trial primary completion date: Jun 2026 --> Sep 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Datroway (datopotamab deruxtecan-dlnk)
    2d
    JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=119, Completed, Shanghai Junshi Bioscience Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • carboplatin • paclitaxel • docetaxel • Loqtorzi (toripalimab-tpzi) • pemetrexed • etoposide IV • tifcemalimab (TAB004)
    2d
    A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC (clinicaltrials.gov)
    P3, N=162, Terminated, Bio-Thera Solutions | N=676 --> 162 | Trial completion date: Oct 2028 --> Jul 2025 | Recruiting --> Terminated | Trial primary completion date: Jul 2027 --> Jul 2025; The new regulatory developments have led us to conclude that a Phase 3 study is no longer necessary for the development and approval of BAT3306. As such, to ensure effective use of clinical resources, we are terminating this study.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed
    2d
    J5M-OX-JOXA: A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=340, Recruiting, Eli Lilly and Company | Trial completion date: Oct 2027 --> Dec 2028 | Trial primary completion date: Oct 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed
    3d
    A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2 trial
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • SYS6010
    6d
    STK-012-101: Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers (clinicaltrials.gov)
    P1/2, N=364, Recruiting, Synthekine | Phase classification: P1 --> P1/2 | N=202 --> 364 | Trial completion date: Oct 2027 --> Jan 2029 | Trial primary completion date: Oct 2027 --> Jan 2029
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • STK-012
    6d
    KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) (clinicaltrials.gov)
    P2, N=130, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2 trial
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • pemetrexed • MK-1084
    7d
    Krascendo 170: A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (clinicaltrials.gov)
    P1/2, N=320, Recruiting, Hoffmann-La Roche | N=240 --> 320
    Enrollment change
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • divarasib (RG6330)
    7d
    Role and Mechanism of Hyaluronic Acid-modified Milk Exosomes in Reversing Pemetrexed Resistance in Lung Adenocarcinoma Cells (PubMed, Zhongguo Fei Ai Za Zhi)
    HA-mEXO carrying ZNF516 suppress ABCC5 expression, thereby enhancing the sensitivity of A549 and PC-9 LAUD drug-resistant cells to PMX.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6) • CD44 (CD44 Molecule) • ABCC5 (ATP Binding Cassette Subfamily C Member 5)
    |
    pemetrexed
    8d
    Real-World Comparative Study of Atezolizumab-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer. (PubMed, Cancers (Basel))
    These findings suggest that ABCP may offer superior efficacy in specific non-small cell lung cancer subgroups, while ACnP remains a valuable option for patients requiring a more tolerable safety profile.
    Clinical • Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • EGFR positive
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed
    8d
    NIRVANA-LUNG: PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=327, Recruiting, UNICANCER | Active, not recruiting --> Recruiting | Trial completion date: Jul 2027 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK translocation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed